Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity
SourceRheumatology, 58, 3, (2019), pp. 427-431
Article / Letter to editor
Display more detailsDisplay less details
SubjectAll institutes and research themes of the Radboud University Medical Center; Radboudumc 18: Healthcare improvement science RIHS: Radboud Institute for Health Sciences; Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.